Company / Total Assets
Anixa Biosciences Inc Total Assets History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$21.6M
FY2024
5-year range
$6.3M / $30.4M
FY2020-FY2024
Trend
-15.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 10 years, ranging from $6M in FY2016 to $30M in FY2022.
Based on SEC 10-K filings.
$22M in FY2024 with a 10-year CAGR of +9.1%.
Declined from $30M to $22M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +28.0%
- 10-Year CAGR
- +9.1%
Key checks
Key Insights
- 5-year CAGR of +28.0%, indicating consistent growth.
- In FY2024, total assets decreased 15.4% year-over-year.
- Peak total assets was recorded in FY2022.
- Lowest total assets in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $21.6M | -15.4% |
| FY2023 | $25.5M | -16.1% |
| FY2022 | $30.4M | +221.7% |
| FY2020 | $9.5M | +50.2% |
| FY2019 | $6.3M | -2.4% |
| FY2018 | $6.4M | -26.8% |
| FY2017 | $8.8M | +56.6% |
| FY2016 | $5.6M | -39.7% |
| FY2015 | $9.3M | +3.1% |
| FY2014 | $9.1M | +60.0% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026